ChiRex to supply Glaxo Wellcome with intermediates from former Glaxo plant in Scotland.
CHIREX TO SUPPLY RANITIDINE INTERMEDIATES TO GLAXO WELLCOME from a former Glaxo plant in Annan, Scotland, under a letter of intent announced July 7. The Annan facility produces pharmaceutical intermediates used in several Glaxo Wellcome products, including Tritec (ranitidine bismuth citrate, called Pylorid in Europe) and Zantac (ranitidine). Under the agreement, ChiRex will purchase the Annan plant but will continue to supply Glaxo Wellcome with the intermediates for at least five years.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth